nilvadipine has been researched along with Chronic Disease in 6 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the efficacy of nilvadipine, a calcium channel inhibitor, for psychiatric symptoms and tardive dyskinesia in 30 patients with chronic schizophrenia in a placebo-controlled double-blind crossover study." | 9.08 | Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study. off. ( Asai, M; Ashikari, I; Kanba, S; Ohnishi, K; Yagi, G; Yamada, K, 1996) |
| "Because blood viscosity is significantly raised in patients with essential hypertension (EH), the hemorheological effects of a 4-month chronic treatment with the calcium antagonist nilvadipine (FK 235, 5-isopropyl-3-methyl-2-cyano-1,4-dihydro-6-methyl-4- (m-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 75530-68-6) on elevated blood viscosity was investigated prospectively in patients with EH, and compared with those in normotensive individuals of similar age." | 9.08 | Chronic hemorheological effects of the calcium antagonist nilvadipine in essential hypertension. ( Izumi, Y; Kitadai, M; Satoh, K; Takahashi, T; Tsuda, Y, 1997) |
| "The effect of nilvadipine, a newly developed calcium antagonist, on regional cerebral blood flow (rCBF) was investigated in 7 patients with chronic cerebral infarction." | 7.68 | Effect of single oral administration of nilvadipine on cerebral blood flow in chronic cerebral infarction. ( Bokura, K; Kobayashi, S; Murao, M; Okada, K; Suyama, N; Tsunematsu, T; Yamaguchi, S, 1992) |
| "Nilvadipine is a calcium channel inhibitor used commonly for the treatment of cerebrovascular insufficiency." | 5.29 | Effectiveness of nilvadipine in two cases of chronic schizophrenia. ( Asai, M; Ashikari, I; Kanba, S; Onishi, K; Yagi, G; Yamada, K, 1995) |
| "We investigated the efficacy of nilvadipine, a calcium channel inhibitor, for psychiatric symptoms and tardive dyskinesia in 30 patients with chronic schizophrenia in a placebo-controlled double-blind crossover study." | 5.08 | Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study. off. ( Asai, M; Ashikari, I; Kanba, S; Ohnishi, K; Yagi, G; Yamada, K, 1996) |
| "Because blood viscosity is significantly raised in patients with essential hypertension (EH), the hemorheological effects of a 4-month chronic treatment with the calcium antagonist nilvadipine (FK 235, 5-isopropyl-3-methyl-2-cyano-1,4-dihydro-6-methyl-4- (m-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 75530-68-6) on elevated blood viscosity was investigated prospectively in patients with EH, and compared with those in normotensive individuals of similar age." | 5.08 | Chronic hemorheological effects of the calcium antagonist nilvadipine in essential hypertension. ( Izumi, Y; Kitadai, M; Satoh, K; Takahashi, T; Tsuda, Y, 1997) |
| "The effect of nilvadipine, a newly developed calcium antagonist, on regional cerebral blood flow (rCBF) was investigated in 7 patients with chronic cerebral infarction." | 3.68 | Effect of single oral administration of nilvadipine on cerebral blood flow in chronic cerebral infarction. ( Bokura, K; Kobayashi, S; Murao, M; Okada, K; Suyama, N; Tsunematsu, T; Yamaguchi, S, 1992) |
| "Fourteen normotensive patients with liver disease (6 with cirrhosis and 8 with chronic hepatitis) and 7 healthy volunteers were given a single oral dose of nilvadipine 2 mg." | 3.68 | Elevated plasma nilvadipine concentration after single and chronic oral administration to patients with chronic liver disease. ( Fujishima, M; Ito, Y; Kikuchi, M; Kobayashi, K; Takata, Y; Tsukashima, A; Ueno, M; Yoshizumi, T, 1992) |
| "Nilvadipine is a calcium channel inhibitor used commonly for the treatment of cerebrovascular insufficiency." | 1.29 | Effectiveness of nilvadipine in two cases of chronic schizophrenia. ( Asai, M; Ashikari, I; Kanba, S; Onishi, K; Yagi, G; Yamada, K, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamada, K | 2 |
| Kanba, S | 2 |
| Ashikari, I | 2 |
| Ohnishi, K | 1 |
| Yagi, G | 2 |
| Asai, M | 2 |
| Onishi, K | 1 |
| Tsuda, Y | 1 |
| Satoh, K | 1 |
| Kitadai, M | 1 |
| Izumi, Y | 1 |
| Takahashi, T | 1 |
| Tomita, G | 1 |
| Niwa, Y | 1 |
| Shinohara, H | 1 |
| Hayashi, N | 1 |
| Yamamoto, T | 1 |
| Kitazawa, Y | 1 |
| Kobayashi, S | 1 |
| Yamaguchi, S | 1 |
| Okada, K | 1 |
| Suyama, N | 1 |
| Bokura, K | 1 |
| Murao, M | 1 |
| Tsunematsu, T | 1 |
| Takata, Y | 1 |
| Yoshizumi, T | 1 |
| Ito, Y | 1 |
| Kikuchi, M | 1 |
| Ueno, M | 1 |
| Tsukashima, A | 1 |
| Kobayashi, K | 1 |
| Fujishima, M | 1 |
3 trials available for nilvadipine and Chronic Disease
| Article | Year |
|---|---|
Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study. off.
Topics: Adult; Aged; Calcium Channel Blockers; Chronic Disease; Cross-Over Studies; Double-Blind Method; Dys | 1996 |
Chronic hemorheological effects of the calcium antagonist nilvadipine in essential hypertension.
Topics: Blood Pressure; Blood Viscosity; Calcium Channel Blockers; Chronic Disease; Female; Hematocrit; Huma | 1997 |
Changes in optic nerve head blood flow and retrobular hemodynamics following calcium-channel blocker treatment of normal-tension glaucoma.
Topics: Adult; Aged; Aged, 80 and over; Blood Flow Velocity; Calcium Channel Blockers; Chronic Disease; Cili | 1999 |
3 other studies available for nilvadipine and Chronic Disease
| Article | Year |
|---|---|
Effectiveness of nilvadipine in two cases of chronic schizophrenia.
Topics: Calcium Channel Blockers; Chronic Disease; Dyskinesia, Drug-Induced; Humans; Male; Middle Aged; Nife | 1995 |
Effect of single oral administration of nilvadipine on cerebral blood flow in chronic cerebral infarction.
Topics: Administration, Oral; Aged; Aged, 80 and over; Blood Pressure; Calcium Channel Blockers; Cerebral In | 1992 |
Elevated plasma nilvadipine concentration after single and chronic oral administration to patients with chronic liver disease.
Topics: Administration, Oral; Calcium Channel Blockers; Chronic Disease; Hemodynamics; Hepatitis; Humans; Li | 1992 |